Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kimmo Porkka

Showing results (61-70 of 142) with videos related to

Pageof 15
Sort By:
Plos One|August 23, 2011
Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profileAnna Kreutzman, Peter Rohon, Edgar Faber, et al.
Nature|February 18, 2015
Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformationTea Pemovska, Eric Johnson, Mika Kontro, et al.
Blood Advances|February 12, 2020
Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemiaShady Adnan Awad, Matti Kankainen, Teija Ojala, et al.
Cytotherapy|June 25, 2017
Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansionTanja Kaartinen, Annu Luostarinen, Pilvi Maliniemi, et al.
Cytotherapy|April 16, 2017
Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansionTanja Kaartinen, Annu Luostarinen, Pilvi Maliniemi, et al.
Haematologica|April 29, 2022
Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemiaHelena Hohtari, Niels Pallisgaard, Matti Kankainen, et al.
European Journal of Haematology|December 31, 2013
Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular responsePerttu Koskenvesa, Anna Kreutzman, Peter Rohon, et al.
Cell Reports. Medicine|April 23, 2024
Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemiaShady Adnan Awad, Olli Dufva, Jay Klievink, et al.
Oncotarget|September 17, 2017
Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testingMuntasir Mamun Majumder, Raija Silvennoinen, Pekka Anttila, et al.
Leukemia|July 18, 2020
KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemiaDisha Malani, Bhagwan Yadav, Ashwini Kumar, et al.
Pageof 15

Showing results (61-70 of 142) with videos related to

Sort By:
Pageof 15
Plos One|August 23, 2011
Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profileAnna Kreutzman, Peter Rohon, Edgar Faber, et al.
Nature|February 18, 2015
Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformationTea Pemovska, Eric Johnson, Mika Kontro, et al.
Blood Advances|February 12, 2020
Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemiaShady Adnan Awad, Matti Kankainen, Teija Ojala, et al.
Cytotherapy|June 25, 2017
Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansionTanja Kaartinen, Annu Luostarinen, Pilvi Maliniemi, et al.
Cytotherapy|April 16, 2017
Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansionTanja Kaartinen, Annu Luostarinen, Pilvi Maliniemi, et al.
Haematologica|April 29, 2022
Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemiaHelena Hohtari, Niels Pallisgaard, Matti Kankainen, et al.
European Journal of Haematology|December 31, 2013
Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular responsePerttu Koskenvesa, Anna Kreutzman, Peter Rohon, et al.
Cell Reports. Medicine|April 23, 2024
Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemiaShady Adnan Awad, Olli Dufva, Jay Klievink, et al.
Oncotarget|September 17, 2017
Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testingMuntasir Mamun Majumder, Raija Silvennoinen, Pekka Anttila, et al.
Leukemia|July 18, 2020
KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemiaDisha Malani, Bhagwan Yadav, Ashwini Kumar, et al.
Pageof 15